Evidence map›Paper›PMID 36145335›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

An In Vitro Model for Characterization of Drug Permeability across the Tympanic Membrane.

Joachim G S Veit, Bhaskar Birru, Ruby Singh, Elizabeth M Arrigali, Monica A Serban

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Frontiers in pharmacology · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joachim G S VeitDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA.ORCID 0000-0001-5908-0648
Bhaskar BirruDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA.
Ruby SinghDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA.
Elizabeth M ArrigaliDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA.
Monica A SerbanDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA.
University of Montana · US

Funding

Office of Naval Research N00014-20-1-2874
6 · The paper itself

Abstract

Otic disorders, such as otitis media and hearing loss, affect a substantial portion of the global population. Despite this, oto-therapeutics, in particular those intended to treat hearing loss, have seen limited development and innovation. A significant factor to this is likely a result of the inherent costs and complexities of drug discovery and development. With in vitro 3D tissue models seeing increased utility for the rapid, high-throughput screening of drug candidates, it stands to reason that the field of otology could greatly benefit from such innovations. In this study, we propose and describe an in vitro 3D model, designed using a physiologically based approach, which we suggest can be used to estimate drug permeability across human tympanic membranes (TM). We characterize the permeability properties of several template drugs in this model under various growth and storage conditions. The availability of such cost-effective, rapid, high-throughput screening tools should allow for increased innovation and the discovery of novel drug candidates over the currently used animal models. In the context of this TM permeation model, it may promote the development of topical drugs and formulations that can non-invasively traverse the TM and provide tissue-targeted drug delivery as an alternative to systemic treatment, an objective which has seen limited study until present.

Indexed as

drug permeationin vitro 3D tissue modeloto-therapeuticstympanic membrane

Identifiers

PMID36145335
PMCPMC9503993
OpenAlexW4295007732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.